TFRC and neoplasm: However, it is worth noting that there is a novel dual-targeting Ru(IV)-based agent under evaluation in preclinical studies, endowed with antitumour and antimetastatic activity exerted via the PARP pathway and targeting tumour sites through both the enhanced permeability and retention (EPR) effect and transferrin receptor interaction [177].